Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to 0.88.

  • Lipocine's Equity Ratio fell 473.71% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 473.71%. This contributed to the annual value of 0.93 for FY2024, which is 533.01% up from last year.
  • Lipocine's Equity Ratio amounted to 0.88 in Q3 2025, which was down 473.71% from 0.92 recorded in Q2 2025.
  • Lipocine's Equity Ratio's 5-year high stood at 0.95 during Q3 2022, with a 5-year trough of 0.76 in Q2 2021.
  • For the 5-year period, Lipocine's Equity Ratio averaged around 0.9, with its median value being 0.92 (2025).
  • In the last 5 years, Lipocine's Equity Ratio soared by 16850.51% in 2021 and then plummeted by 669.97% in 2023.
  • Over the past 5 years, Lipocine's Equity Ratio (Quarter) stood at 0.87 in 2021, then rose by 9.32% to 0.95 in 2022, then decreased by 6.7% to 0.89 in 2023, then grew by 5.33% to 0.93 in 2024, then fell by 5.67% to 0.88 in 2025.
  • Its Equity Ratio was 0.88 in Q3 2025, compared to 0.92 in Q2 2025 and 0.94 in Q1 2025.